• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

NCI-60 中的靶向肿瘤学研究药物：基于表型系统的资源。

Targeted Investigational Oncology Agents in the NCI-60: A Phenotypic Systems-based Resource.

机构信息

Division of Cancer Treatment and Diagnosis, NCI, Rockville, Maryland.

Target Validation and Screening Laboratory, Applied and Developmental Research Directorate, Frederick National, Laboratory for Cancer Research, Frederick, Maryland.

出版信息

Mol Cancer Ther. 2023 Nov 1;22(11):1270-1279. doi: 10.1158/1535-7163.MCT-23-0267.

DOI:10.1158/1535-7163.MCT-23-0267
PMID:37550087
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10618733/
Abstract

The NCI-60 human tumor cell line panel has proved to be a useful tool for the global cancer research community in the search for novel chemotherapeutics. The publicly available cell line characterization and compound screening data from the NCI-60 assay have significantly contributed to the understanding of cellular mechanisms targeted by new oncology agents. Signature sensitivity/resistance patterns generated for a given chemotherapeutic agent against the NCI-60 panel have long served as fingerprint presentations that encompass target information and the mechanism of action associated with the tested agent. We report the establishment of a new public NCI-60 resource based on the cell line screening of a large and growing set of 175 FDA-approved oncology drugs (AOD) plus >825 clinical and investigational oncology agents (IOA), representing a diverse set (>250) of therapeutic targets and mechanisms. This data resource is available to the public (https://ioa.cancer.gov) and includes the raw data from the screening of the IOA and AOD collection along with an extensive set of visualization and analysis tools to allow for comparative study of individual test compounds and multiple compound sets.

摘要

NCI-60 人类肿瘤细胞系面板已被证明是全球癌症研究界寻找新型化疗药物的有用工具。NCI-60 测定法中公开提供的细胞系特征描述和化合物筛选数据极大地促进了对新肿瘤学药物靶向的细胞机制的理解。针对给定化疗药物生成的特征敏感性/耐药性模式长期以来一直作为指纹呈现，包含与测试药物相关的目标信息和作用机制。我们报告了一个新的公共 NCI-60 资源的建立，该资源基于对一组不断增长的 175 种 FDA 批准的肿瘤药物 (AOD) 和超过 825 种临床和研究性肿瘤药物 (IOA) 的细胞系筛选，代表了一个多样化的治疗靶点和机制 (>250)。该数据资源对公众开放（https://ioa.cancer.gov），包括 IOA 和 AOD 化合物筛选的原始数据，以及一套广泛的可视化和分析工具，允许对单个测试化合物和多个化合物集进行比较研究。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80e6/10618733/a01e288f9f7a/1270fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80e6/10618733/8d40af9a40e4/1270fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80e6/10618733/98f1e720c8ed/1270fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80e6/10618733/a95dba689744/1270fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80e6/10618733/41e3e15b1c1c/1270fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80e6/10618733/b0464086aa7b/1270fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80e6/10618733/a01e288f9f7a/1270fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80e6/10618733/8d40af9a40e4/1270fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80e6/10618733/98f1e720c8ed/1270fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80e6/10618733/a95dba689744/1270fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80e6/10618733/41e3e15b1c1c/1270fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80e6/10618733/b0464086aa7b/1270fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/80e6/10618733/a01e288f9f7a/1270fig6.jpg

相似文献

1
Targeted Investigational Oncology Agents in the NCI-60: A Phenotypic Systems-based Resource.NCI-60 中的靶向肿瘤学研究药物：基于表型系统的资源。
Mol Cancer Ther. 2023 Nov 1;22(11):1270-1279. doi: 10.1158/1535-7163.MCT-23-0267.
2
Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines.分析美国国立癌症研究所（NCI）60 人肿瘤细胞系panel 中食品和药物管理局批准的抗癌药物。
Mol Cancer Ther. 2010 May;9(5):1451-60. doi: 10.1158/1535-7163.MCT-10-0106. Epub 2010 May 4.
3
Genome-wide analysis of three-way interplay among gene expression, cancer cell invasion and anti-cancer compound sensitivity.全基因组分析基因表达、癌细胞侵袭和抗癌化合物敏感性之间的三向相互作用。
BMC Med. 2013 Apr 16;11:106. doi: 10.1186/1741-7015-11-106.
4
Data mining the NCI cancer cell line compound GI(50) values: identifying quinone subtypes effective against melanoma and leukemia cell classes.挖掘美国国立癌症研究所癌细胞系化合物的半数抑制浓度（GI(50)）值：识别对黑色素瘤和白血病细胞类型有效的醌亚型。
J Chem Inf Comput Sci. 2003 Sep-Oct;43(5):1652-67. doi: 10.1021/ci034050+.
5
Update on NCI in vitro drug screen utilities.国立癌症研究所体外药物筛选应用的最新进展。
Eur J Cancer. 2004 Apr;40(6):785-93. doi: 10.1016/j.ejca.2003.11.022.
6
RNA Sequencing of the NCI-60: Integration into CellMiner and CellMiner CDB.NCI-60 的 RNA 测序：整合到 CellMiner 和 CellMiner CDB 中。
Cancer Res. 2019 Jul 1;79(13):3514-3524. doi: 10.1158/0008-5472.CAN-18-2047. Epub 2019 May 21.
7
ROADMAPS: An Online Database of Response Data, Dosing Regimens, and Toxicities of Approved Oncology Drugs as Single Agents to Guide Preclinical In Vivo Studies.ROADMAPS：一个在线数据库，包含获批肿瘤药物单药治疗的应答数据、剂量方案和毒性数据，旨在指导临床前体内研究。
Cancer Res. 2022 Jun 15;82(12):2219-2225. doi: 10.1158/0008-5472.CAN-21-4151.
8
HTS384 NCI60: The Next Phase of the NCI60 Screen.HTS384 NCI60：NCI60筛选的下一阶段
Cancer Res. 2024 Aug 1;84(15):2403-2416. doi: 10.1158/0008-5472.CAN-23-3031.
9
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区，服用抗叶酸抗疟药物的人群中，叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
10
New tools for old drugs: Functional genetic screens to optimize current chemotherapy.旧药新用的工具：功能遗传学筛选以优化现有化疗药物。
Drug Resist Updat. 2018 Jan;36:30-46. doi: 10.1016/j.drup.2018.01.001. Epub 2018 Jan 12.

引用本文的文献

1
RNA processing kinase inhibitors and epigenetic inhibitors in combination with oncology drugs or investigational agents in multi-cell type patient-derived tumor cell line spheroids.RNA加工激酶抑制剂和表观遗传抑制剂与肿瘤药物或研究性药物联合用于多细胞类型患者来源的肿瘤细胞系球体。
Cancer Chemother Pharmacol. 2025 Sep 12;95(1):85. doi: 10.1007/s00280-025-04800-w.
2
Targeted therapy combinations with ipatasertib in multi-cell type 3D tumor spheroid models.在多细胞类型3D肿瘤球体模型中使用ipatasertib的靶向治疗联合方案。
Acad Oncol. 2025;2(2). doi: 10.20935/acadonco7726. Epub 2025 Jun 17.
3
Polymerase Ѳ inhibitors combinations with approved and investigational agents in patient-derived tumor multi-cell type (mct) spheroids.

本文引用的文献

1
Hallmarks of Cancer: New Dimensions.癌症的特征：新视角。
Cancer Discov. 2022 Jan;12(1):31-46. doi: 10.1158/2159-8290.CD-21-1059.
2
Ibrutinib combinations in CLL therapy: scientific rationale and clinical results.伊布替尼联合治疗 CLL：科学依据和临床结果。
Blood Cancer J. 2021 Apr 29;11(4):79. doi: 10.1038/s41408-021-00467-7.
3
Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to.Bcr-Abl 变构抑制剂：我们的现状和未来展望。
聚合酶Ѳ抑制剂与已批准和正在研究的药物在患者来源的肿瘤多细胞类型（mct）球体中的联合应用。
Exp Mol Pathol. 2025 Jun 27;143:104978. doi: 10.1016/j.yexmp.2025.104978.
4
RNA processing kinase inhibitors and epigenetic inhibitors in combination with oncology drugs or investigational agents in multi-cell type patient-derived tumor cell line spheroids.RNA加工激酶抑制剂和表观遗传抑制剂与肿瘤药物或研究性药物联合用于多细胞类型患者来源的肿瘤细胞系球体。
Res Sq. 2025 May 15:rs.3.rs-6602839. doi: 10.21203/rs.3.rs-6602839/v1.
5
Combinatorial screen of targeted agents with the PI3K inhibitors inavolisib, alpelisib, duvelisib, and copanlisib in multi-cell type tumor spheroids.在多细胞类型肿瘤球体中，将靶向药物与PI3K抑制剂（依维莫司、阿培利司、度维利塞和库潘尼西）进行组合筛选。
SLAS Discov. 2025 Apr;32:100222. doi: 10.1016/j.slasd.2025.100222. Epub 2025 Feb 23.
6
Combination screen in multi-cell type tumor spheroids reveals interaction between aryl hydrocarbon receptor antagonists and E1 ubiquitin-activating enzyme inhibitor.多细胞类型肿瘤球体的联合筛选揭示了芳香烃受体拮抗剂与 E1 泛素激活酶抑制剂之间的相互作用。
SLAS Discov. 2024 Oct;29(7):100186. doi: 10.1016/j.slasd.2024.100186. Epub 2024 Oct 1.
7
Structure elucidation, absolute configuration, and biological evaluation of cyclic peroxides from the sponge Plakinastrella sp.从海绵 Plakinastrella sp. 中分离得到的环状过氧化物的结构阐明、绝对构型和生物评价
Bioorg Med Chem Lett. 2024 Nov 15;113:129963. doi: 10.1016/j.bmcl.2024.129963. Epub 2024 Sep 14.
8
Paralogue-Selective Degradation of the Lysine Acetyltransferase EP300.赖氨酸乙酰转移酶EP300的旁系同源物选择性降解
JACS Au. 2024 Jul 29;4(8):3094-3103. doi: 10.1021/jacsau.4c00442. eCollection 2024 Aug 26.
9
HTS384 NCI60: The Next Phase of the NCI60 Screen.HTS384 NCI60：NCI60筛选的下一阶段
Cancer Res. 2024 Aug 1;84(15):2403-2416. doi: 10.1158/0008-5472.CAN-23-3031.
10
Paralogue-selective degradation of the lysine acetyltransferase EP300.赖氨酸乙酰转移酶EP300的旁系同源物选择性降解
bioRxiv. 2024 May 5:2024.05.03.592353. doi: 10.1101/2024.05.03.592353.
Molecules. 2020 Sep 14;25(18):4210. doi: 10.3390/molecules25184210.
4
Biochemical characterization of tirabrutinib and other irreversible inhibitors of Bruton's tyrosine kinase reveals differences in on - and off - target inhibition.替拉鲁替尼和其他布鲁顿酪氨酸激酶不可逆抑制剂的生化特征揭示了靶内和靶外抑制的差异。
Biochim Biophys Acta Gen Subj. 2020 Apr;1864(4):129531. doi: 10.1016/j.bbagen.2020.129531. Epub 2020 Jan 15.
5
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.赞布替尼（BGB-3111）的发现，一种新型、有效且选择性的布鲁顿酪氨酸激酶共价抑制剂。
J Med Chem. 2019 Sep 12;62(17):7923-7940. doi: 10.1021/acs.jmedchem.9b00687. Epub 2019 Aug 19.
6
Natural products targeting the p53-MDM2 pathway and mutant p53: Recent advances and implications in cancer medicine.靶向p53-MDM2通路和突变型p53的天然产物：癌症医学的最新进展及意义
Genes Dis. 2018 Jul 20;5(3):204-219. doi: 10.1016/j.gendis.2018.07.002. eCollection 2018 Sep.
7
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.BTK 抑制剂 ARQ 531 靶向伊布替尼耐药的 CLL 和 Richter 转化。
Cancer Discov. 2018 Oct;8(10):1300-1315. doi: 10.1158/2159-8290.CD-17-1409. Epub 2018 Aug 9.
8
Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile.阿卡拉布替尼（ACP-196）：一种具有独特选择性和体内药效学特征的共价布鲁顿酪氨酸激酶抑制剂。
J Pharmacol Exp Ther. 2017 Nov;363(2):240-252. doi: 10.1124/jpet.117.242909. Epub 2017 Sep 7.
9
The National Cancer Institute ALMANAC: A Comprehensive Screening Resource for the Detection of Anticancer Drug Pairs with Enhanced Therapeutic Activity.美国国家癌症研究所ALMANAC：用于检测具有增强治疗活性的抗癌药物组合的综合筛查资源。
Cancer Res. 2017 Jul 1;77(13):3564-3576. doi: 10.1158/0008-5472.CAN-17-0489. Epub 2017 Apr 26.
10
Optimization of a Series of Bivalent Triazolopyridazine Based Bromodomain and Extraterminal Inhibitors: The Discovery of (3R)-4-[2-[4-[1-(3-Methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153).一系列基于二价三唑并哒嗪的溴结构域和额外末端抑制剂的优化：(3R)-4-[2-[4-[1-(3-甲氧基-[1,2,4]三唑并[4,3-b]哒嗪-6-基)-4-哌啶基]苯氧基]乙基]-1,3-二甲基-哌嗪-2-酮（AZD5153）的发现
J Med Chem. 2016 Sep 8;59(17):7801-17. doi: 10.1021/acs.jmedchem.6b00070. Epub 2016 Aug 24.